Incyte’s (INCY) tafasitamab-cxix was granted FDA orphan designation as a treatment of nodal marginal zone lymphoma, according to a post to the agency’s website.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks